CERC:NSD-Cerecor Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.18

Change

0.00 (0.00)%

Market Cap

USD 0.28B

Volume

0.25M

Avg Analyst Target

USD 7.00 (+221.10%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis; CERC-006, an oral mTORC1/2 inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody that is in phase 2 clinical trial for the treatment of COVID-19 acute respiratory distress syndrome, as well as for the treatment of pediatric-onset Crohn's diseases. In addition, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. Cerecor Inc. has a collaboration agreement with The Frontiers in Congenital Disorders of Glycosylation Consortium on pivotal trial of CERC-801 for the treatment of Phosphoglucomutase-1 deficiency related congenital disorders of glycosylation. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland. Address: 540 Gaither Road, Rockville, MD, United States, 20850

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD131.81B 38.58 31.39
BNTX BioNTech SE

N/A

USD67.50B 15.50 10.94
REGN Regeneron Pharmaceuticals Inc

N/A

USD61.22B 10.34 7.53
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD48.54B 24.20 15.87
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

N/A

USD35.36B N/A N/A
SGEN Seagen Inc

N/A

USD31.19B 53.49 43.63
GMAB Genmab A/S

N/A

USD30.33B 78.11 8.55
ALNY Alnylam Pharmaceuticals Inc

N/A

USD23.60B N/A N/A
RPRX Royalty Pharma plc

N/A

USD22.77B 30.36 12.47

ETFs Containing CERC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.42% 52% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.42% 52% F 24% F
Trailing 12 Months  
Capital Gain -6.03% 50% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.03% 50% F 22% F
Trailing 5 Years  
Capital Gain -46.17% 38% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.17% 38% F 14% F
Average Annual (5 Year Horizon)  
Capital Gain 106.07% 89% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 106.07% 88% B+ 93% A
Risk Return Profile  
Volatility (Standard Deviation) 221.56% 10% F 6% F
Risk Adjusted Return 47.88% 76% C 65% D
Market Capitalization 0.28B 47% F 39% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 141.30 8% F 8% F
Price/Book Ratio 13.79 10% F 9% F
Price / Cash Flow Ratio -7.03 51% F 68% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -213.81% 10% F 13% F
Return on Invested Capital -195.36% 7% F 3% F
Return on Assets -72.52% 6% F 2% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.29 51% F 35% F
Short Percent 4.27% 54% F 39% F
Beta 1.44 44% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector